• Login
    View Item 
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2015 RD&E publications
    • View Item
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2015 RD&E publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis

    Thumbnail
    URI
    http://hdl.handle.net/11287/618029
    Author
    Perry, Mandy
    McDonald, Timothy J.
    Cudmore, Adrian
    Ahmad, Tariq
    Date
    2015-11-02
    Journal
    Clinical Laboratory International
    Type
    Journal Article
    Publisher
    Clinical Laboratory International
    Metadata
    Show full item record
    Abstract
    The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease, being very effective in many patients. Some patients experience problems such as loss of response, which is associated with production of antibodies to the therapy. Measuring trough drug and antibody concentrations may direct patient management in future.
    Citation
    Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis. 2015. Clinical Laboratory International
    Publisher URL
    http://www.cli-online.com/index.php?id=4173
    Collections
    • 2015 RD&E publications
    • Exeter Clinical Laboratory International (Blood Sciences, Genetics, Cellular Pathology & Microbiology)
    • Gastroenterology

    Browse

    All of RD&E Research RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2023  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV